Terns Pharmaceuticals (NASDAQ:TERN) Upgraded to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Terns Pharmaceuticals to a sell rating, adding to a wave of mixed analyst sentiment around the stock.
• Recent analyst actions have been mostly cautious, with several firms cutting ratings to hold; the consensus view is now Hold with an average price target of $55.14.
• Terns shares recently traded near their 52-week high at $52.95, after the company reported quarterly EPS of ($0.24), beating expectations of ($0.30).

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) was upgraded by stock analysts at Wall Street Zen to a "sell" rating in a report issued on Saturday.

Other analysts have also recently issued research reports about the company. Citizens Jmp cut Terns Pharmaceuticals from a "market outperform" rating to a "hold" rating in a research report on Thursday, March 26th. HC Wainwright restated a "neutral" rating and issued a $53.00 price target (down from $60.00) on shares of Terns Pharmaceuticals in a research report on Wednesday, March 25th. Leerink Partners cut Terns Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 8th. JPMorgan Chase & Co. increased their target price on Terns Pharmaceuticals from $44.00 to $44.50 and gave the stock an "overweight" rating in a research report on Tuesday, April 14th. Finally, TD Cowen cut Terns Pharmaceuticals from a "buy" rating to a "hold" rating and set a $53.00 target price for the company. in a research report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Terns Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $55.14.

Terns Pharmaceuticals Price Performance

Shares of TERN opened at $52.95 on Friday. The business has a 50-day simple moving average of $49.68 and a two-hundred day simple moving average of $37.90. The stock has a market cap of $6.12 billion, a price-to-earnings ratio of -51.41 and a beta of -0.37. Terns Pharmaceuticals has a 52 week low of $2.65 and a 52 week high of $53.19.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. On average, equities analysts anticipate that Terns Pharmaceuticals will post -1.22 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Emil Kuriakose sold 942 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the sale, the insider owned 105,673 shares in the company, valued at approximately $5,574,250.75. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Amy L. Burroughs sold 14,583 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the sale, the chief executive officer owned 288,976 shares of the company's stock, valued at $13,498,068.96. This represents a 4.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 30,108 shares of company stock valued at $1,302,370 in the last quarter. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Terns Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Terns Pharmaceuticals during the 4th quarter valued at approximately $25,000. Fifth Third Bancorp purchased a new position in Terns Pharmaceuticals during the 1st quarter valued at approximately $32,000. GAMMA Investing LLC grew its holdings in Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company's stock valued at $35,000 after buying an additional 770 shares in the last quarter. Engineers Gate Manager LP purchased a new position in Terns Pharmaceuticals during the 2nd quarter valued at approximately $41,000. Finally, iA Global Asset Management Inc. purchased a new position in Terns Pharmaceuticals during the 4th quarter valued at approximately $43,000. Hedge funds and other institutional investors own 98.26% of the company's stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.